📊 APGE Key Takeaways
Is Apogee Therapeutics, Inc. (APGE) a Good Investment?
Apogee Therapeutics is a pre-revenue biopharmaceutical company with severe cash burn and negative profitability metrics that indicate an unsustainable business model. With operating losses of $285.6M and free cash flow of -$232.6M, the company is consuming capital at an alarming rate despite having only $131.5M in cash reserves. The lack of any revenue generation combined with mounting losses raises fundamental questions about the company's path to profitability and viability.
Apogee Therapeutics has weak current profitability, with no revenue, large operating losses, and deeply negative free cash flow, which is typical of a clinical-stage biotech but still a major fundamental constraint. The balance sheet is a meaningful offset: very high liquidity, minimal liabilities, and a large asset base provide runway to fund development without obvious near-term balance sheet stress. Fundamentally, the story depends on whether pipeline progress eventually converts cash burn into durable revenue growth.
Why Buy Apogee Therapeutics, Inc. Stock? APGE Key Strengths
- Strong liquidity position with current ratio of 26.57x and $131.5M cash reserves
- Moderate debt load with total liabilities of only $33.3M relative to asset base
- Significant insider activity with 13 Form 4 filings in last 90 days suggesting management confidence
- Exceptionally strong liquidity, with 26.57x current and quick ratios indicating ample near-term funding capacity
- Very low balance-sheet leverage, with only $33.25M of liabilities against $937.13M of assets
- Large cash position of $131.55M plus a substantial asset base supports ongoing R&D execution
APGE Stock Risks: Apogee Therapeutics, Inc. Investment Risks
- No revenue generation with operating losses of $285.6M indicating pre-commercial stage company
- Negative free cash flow of -$232.6M means cash runway of approximately 7 months at current burn rate
- Highly negative ROA of -27.3% reflects severe asset inefficiency and value destruction
- Net loss of $255.8M with no path to profitability demonstrated in available financial data
- No revenue base, leaving the company fully dependent on external funding and pipeline advancement
- Heavy losses, including -$285.60M operating income and -$232.60M free cash flow, indicate significant cash burn
- Worsening diluted EPS and negative ROA show weak capital efficiency and limited visibility on profitability
Key Metrics to Watch
- Time to positive operating cash flow and path to revenue generation
- Cash burn rate and remaining cash runway duration
- Clinical trial progress and regulatory milestones for pipeline candidates
- Quarterly operating cash burn and free cash flow trend
- Any emergence of revenue or major improvement in operating loss as pipeline programs mature
Apogee Therapeutics, Inc. (APGE) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 26.57x current ratio provides a solid financial cushion.
APGE Profit Margin, ROE & Profitability Analysis
APGE vs Healthcare Sector: How Apogee Therapeutics, Inc. Compares
How Apogee Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Apogee Therapeutics, Inc. Stock Overvalued? APGE Valuation Analysis 2026
Based on fundamental analysis, Apogee Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Apogee Therapeutics, Inc. Balance Sheet: APGE Debt, Cash & Liquidity
APGE Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Apogee Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-3.36 indicates the company is currently unprofitable.
APGE Revenue Growth, EPS Growth & YoY Performance
Apogee Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
APGE SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Apogee Therapeutics, Inc. (CIK: 0001974640)
📋 Recent SEC Filings
❓ Frequently Asked Questions about APGE
What is the AI rating for APGE?
Apogee Therapeutics, Inc. (APGE) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (HOLD) with 82% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are APGE's key strengths?
Claude: Strong liquidity position with current ratio of 26.57x and $131.5M cash reserves. Moderate debt load with total liabilities of only $33.3M relative to asset base. ChatGPT: Exceptionally strong liquidity, with 26.57x current and quick ratios indicating ample near-term funding capacity. Very low balance-sheet leverage, with only $33.25M of liabilities against $937.13M of assets.
What are the risks of investing in APGE?
Claude: No revenue generation with operating losses of $285.6M indicating pre-commercial stage company. Negative free cash flow of -$232.6M means cash runway of approximately 7 months at current burn rate. ChatGPT: No revenue base, leaving the company fully dependent on external funding and pipeline advancement. Heavy losses, including -$285.60M operating income and -$232.60M free cash flow, indicate significant cash burn.
What is APGE's revenue and growth?
Apogee Therapeutics, Inc. reported revenue of N/A.
Does APGE pay dividends?
Apogee Therapeutics, Inc. does not currently pay dividends.
Where can I find APGE SEC filings?
Official SEC filings for Apogee Therapeutics, Inc. (CIK: 0001974640) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is APGE's EPS?
Apogee Therapeutics, Inc. has a diluted EPS of $-4.22.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is APGE a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Apogee Therapeutics, Inc. has a SELL rating with 82% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is APGE stock overvalued or undervalued?
Valuation metrics for APGE: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy APGE stock in 2026?
Our dual AI analysis gives Apogee Therapeutics, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is APGE's free cash flow?
Apogee Therapeutics, Inc.'s operating cash flow is $-227.5M, with capital expenditures of $5.1M.
How does APGE compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio 26.57 (avg: 2).